PharmaEssentia to Showcase Early-Stage Pipeline Data for Solid Tumor Immunotherapy at SITC Annual Meeting
PharmaEssentia to Present Preclinical Data on PEC2001 and PEC3001 Solid Tumor Immunotherapy Candidates at SITC 2026 PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), has announced…
HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s TAP Program
HeartBeam’s 3D ECG Technology Accepted into FDA’s TAP Program to Advance Heart Attack Assessment HeartBeam, Inc., a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced…
GondolaBio and Children’s Tumor Foundation Partner to Advance Neurofibromatosis Type 1 Program
GondolaBio Partners with Children’s Tumor Foundation to Advance Preclinical NF1 Drug Development Program GondolaBio, a clinical-stage biopharmaceutical company focused on developing innovative medicines for people living with genetic diseases, has…
Povetacicept Phase 3 RAINIER Results Published in NEJM, Presented at ASN Kidney Week 2026
Vertex Pharmaceuticals Reports Positive Phase 3 RAINIER Results for Povetacicept in IgA Nephropathy Published in NEJM Vertex Pharmaceuticals Incorporated has announced the publication of Phase 3 RAINIER trial results for…
Roche Reports Phase 3 Data Showing Sefaxersen Significantly Reduces Proteinuria in IgA Nephropathy
Ionis and Roche Report Phase 3 Sefaxersen Data Showing Significant Proteinuria Reduction in IgA Nephropathy Ionis Pharmaceuticals, Inc. and its partner Roche have announced positive late-breaking results from the ongoing…
Genmab’s Rina-S Shows Significant PFS and OS Benefits in Platinum-Resistant Ovarian Cancer
Genmab Reports Positive Phase 3 RAINFOL-02 Results for Rina-S in Platinum-Resistant Ovarian Cancer Genmab A/S has announced positive topline results from the global Phase 3 RAINFOL™-02 clinical trial evaluating rinatabart…
TG Therapeutics Presents Phase 1 Azer-cel Data in Progressive Multiple Sclerosis at MSToronto 2026
TG Therapeutics Reports Initial Clinical Results for Azer-Cel CAR T-Cell Therapy in Progressive Multiple Sclerosis TG Therapeutics, Inc. has announced initial clinical results from its ongoing Phase 1 study evaluating…
Bristol Myers Squibb Presents Phase 1 BREAKFREE-2 Results for Zolacabtagene Autoleucel in Progressive Multiple Sclerosis at MSToronto 2026
Bristol Myers Squibb Reports Early Safety and Efficacy Results for Investigational CAR T-Cell Therapy Zola-Cel in Multiple Sclerosis Bristol Myers Squibb has announced interim safety and efficacy findings from the…
BeOne Medicines Reports Sustained Survival Benefits with TEVIMBRA-ZIIHERA in First-Line HER2-Positive Gastroesophageal Cancer
BeOne Medicines Reports Longer-Term Survival Benefits for TEVIMBRA-Based Regimens in HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd., a global oncology company, has announced new long-term survival results from the planned second…
Convergent Therapeutics to Present Positive Phase 2 CONV01-α Results at ESMO 2026
Convergent Therapeutics Reports 84% PSA50 Response Rate for CONV01-α in Phase 2 Prostate Cancer Study Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for cancer treatment, has announced…
Neuromodulation Publishes 36-Month CORE-VNS Results Showing Sustained Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
LivaNova Reports 36-Month CORE-VNS Study Results Showing Sustained Seizure Reduction and Improved Quality of Life in Drug-Resistant Epilepsy LivaNova PLC, a medical technology company specializing in therapies for neurological and…
Brenus Pharma Reports Promising Safety and T-Cell Activation Data for STC-1010, With Two Complete Responses in First-Line MSS Metastatic Colorectal Cancer
Brenus Pharma Reports Promising Phase Ia Results for STC-1010 in Metastatic Colorectal Cancer, With 57% Objective Response Rate Brenus Pharma, a clinical-stage biotechnology company developing innovative immunotherapies for cancer, has…